NSRX
AMEX Nasus Pharma Ltd.$3.32 ↑ +0.00 (+0.00%) Trading Up from the previous close of $3.32, $0.12 below the day’s high of $3.44
- YTD change
- -63.72%
- vs 20-day SMA
- -8.49%
- vs 200-day SMA
- -16.48%
Price ranges
Price & Performance
+0.99 (+42.49%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 66.8% away from all-time highs of $9.99
- NSRX is down 64% since the beginning of the year
- NSRX is down 57% over the past 12 months
- NSRX is down 2% over the past 1 month
- 1% of all NSRX investors are betting against NSRX
- Number of investors short NSRX has gone down 10% versus last month
NSRX reads poor: price sits below both the 20- and 200-day averages, short interest is falling month over month, the 12-month move is -57.2%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- -15.31%
- vs 8-day SMA
- -11.56%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Nasus Pharma Ltd. engages in the development of intranasal drugs for emergency medical conditions. It offers Powder-Based Intranasal (PBI) specialized product portfolio, to address acute medical conditions and public health threats. The company was founded by Udi Gilboa and Dalia Megiddo in May 2019 and is headquartered in Tel Aviv, Israel.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.